Amubarvimab Biosimilar - Research Grade

Human

Severe acute respiratory syndrome coronavirus 2

>1mg/ml

IgG1 - kappa

CHO Cells

Adintrevimab Biosimilar - Research Grade (ICH5329), Bebtelovimab Biosimilar - Research Grade (ICH5377), Beludavimab Biosimilar - Research Grade (ICH5385), Canrivitug Biosimilar - Research Grade (ICH5425), Cilgavimab Biosimilar - Research Grade (ICH5438), Crexavibart Biosimilar - Research Grade (ICH5455), Ensovibep Biosimilar - Research Grade (ICH5528), Etesevimab Biosimilar - Research Grade (ICH5535), Gorivitug Biosimilar - Research Grade (ICH5581), Imdevimab Biosimilar - Research Grade (ICH5598), Lomtegovimab Biosimilar - Research Grade (ICH5654), Masavibart Biosimilar - Research Grade (ICH5672), Nepuvibart Biosimilar - Research Grade (ICH5707), Nisfevitug Biosimilar - Research Grade (ICH5714), Ogalvibart Biosimilar - Research Grade (ICH5725), Pemivibart Biosimilar - Research Grade (ICH5767), Plutavimab Biosimilar - Research Grade (ICH5779), Regdanvimab Biosimilar - Research Grade (ICH5813), Romlusevimab Biosimilar - Research Grade (ICH5834), Simaravibart Biosimilar - Research Grade (ICH5865), Sipavibart Biosimilar - Research Grade (ICH5866), Timcevibart Biosimilar - Research Grade (ICH5923), Tixagevimab Biosimilar - Research Grade (ICH5930), Upanovimab Biosimilar - Research Grade (ICH5958), Vebanvibart Biosimilar - Research Grade (ICH5971)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

The SARS-CoV-2 spike protein drives viral attachment and entry and is the central antigen for neutralizing antibody and coronavirus research. Offered as an unconjugated, non-therapeutic analog of amubarvimab, this research-grade anti-SARS-CoV-2 spike recombinant monoclonal antibody is intended for research use only. It is manufactured to in vivo standards, formulated for low endotoxin, and supplied in scalable milligram (mg) to gram (g) quantities for high-throughput and heavy-usage laboratories. Typical uses include viral-neutralization and binding assays, in vitro functional screening, and in vivo infectious-disease models requiring a consistent, reproducible reagent.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Amubarvimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Amubarvimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Amubarvimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Amubarvimab that binds Severe acute respiratory syndrome coronavirus 2.